EGFRBi-armed autologous activated T cells

**EGFRBi-armed autologous activated T cells** are an investigational autologous adoptive cell therapy developed by Roger Williams Medical Center for EGFR-positive advanced solid tumors. Patient peripheral-blood T cells are activated and expanded ex vivo, then armed with a chemically heteroconjugated anti-CD3 × anti-EGFR bispecific antibody composed of OKT3 and cetuximab. The cell-bound bispecific antibody bridges CD3 on the infused T cells to EGFR on tumor cells, promoting redirected, MHC-independent T-cell cytotoxicity against EGFR-expressing cancer cells. The product was evaluated with low-dose aldesleukin and sargramostim in a Phase 1 study of recurrent, refractory, or metastatic advanced solid tumors; that study was terminated. ([clinicaltrials.gov](https://clinicaltrials.gov/api/v2/studies/NCT01081808))

Other names

EGFR BATsEGFRBi-armed ATCanti-CD3 × cetuximab-armed activated T cells